DXB - Research & Valuation, page-182

@singhgu you disrespect the market...in your head you say they didn't understand the DKD results because that's a convenient narrative, but I can tell you the market understood it better than you think, saw through the spin of the "positive top line results" headline (which btw I doubt a commercial big Pharma company could get away with saying in a release if the overall trial failed) and concluded the drug might be a bit of a lemon if it couldn't do better than placebo in a diabetes patient group already at high risk.
>>have you actually been following what's been going on in dkd treatment in the 4 years since the negative dimx trial. >>major drug therapy advancements is the answer, which make the dimx drug now far less compelling than might have been the case back in 2020, big problem for these guys.
>>> I know 2 or 3 people who got in on the story and promise of a pipeline, dkd and copd, but both look to be mirages given the total absence of news in the last 2 years after the company claimed about 2 years ago to be doing x,y, z in both areas. Not a good look at all imo.
GLTAH as they say on this forum...;-)